CLAIMS

1. A complex of eletriptan and a cyclodextrin derivative of formula (I):-



(I)

wherein

R^{1a-g}, R^{2a-g} and R^{3a-g} each independently represent -OH or -$O(CH_2)_4SO_3H$; provided that at least one of R^{1a-g} represents -$O(CH_2)_4SO_3H$: or a pharmaceutically acceptable salt thereof.

2. A complex according to claim 1, wherein the average number of -$O(CH_2)_4SO_3H$ groups per molecule of the derivative of the formula (I) is in the range of from 6.1 to 6.9.

3. A complex according to claim 1 wherein each -$O(CH_2)_4SO_3H$ group present in the derivative of the formula (I) is in the form of an alkali metal salt.

4. A complex according to claim 1 wherein the molar ratio of eletriptan:cyclodextrin derivative of the formula (I) is from 1:1 to 15:1.

5. A complex according to claim 4 wherein the molar ratio of eletriptan:cyclodextrin derivative of the formula (I) is from 1:1 to 10:1.

6. A complex according to claim 1 wherein eletriptan is present in the form of the hemisulphate salt.

7. A pharmaceutical formulation including a complex according to claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

8. A formulation according to claim 7 wherein from 50 to 120 mg/g of eletriptan hemisulphate is present.

9. A formulation according to claim 7 wherein from 15 to 25% weight/weight of the sulphobutylether-beta-cyclodextrin is present.

10. A formulation according to claim 7, including one or more of an anti-oxidant, a co-solvent and an organic polymer.

11. A formulation according to claim 10 wherein the anti-oxidant is ascorbic acid.

12. A formulation according to claim 11 wherein from 0.25 to 0.80% weight/weight of ascorbic acid is present.

13. A formulation according to claim 10 wherein the co-solvent is glycerol.

14. A formulation according to claim 13 wherein from 10.0 to 25.0% weight/weight of glycerol is present.

15. A formulation according to claim 10 wherein the organic polymer is carboxymethylcellulose or polyvinylpyrrolidone.

16. A formulation according to claim 15 wherein from 0.05 to 0.20% weight/weight of carboxymethylcellulose or polyvinylpyrrolidone is present.

17. A formulation according to claim 7 that is in the form of an aqueous solution.

18. An aqueous formulation according to claim 17 that has a pH of from 4.0 to 5.0.

19. A formulation according to claim 7 which is adapted for parenteral administration.

20. A formulation according to claim 7 which is adapted for intranasal administration.

21. A formulation according to claim 7 which is adapted for inhalation.

22. A formulation according to claim 7 that is an aqueous solution comprising:

80mg/g of eletriptan hemisulphate;

20% weight/weight of the sulphobutylether-beta-cyclodextrin derivative of formula (I) having an average sulphobutylether substitution of 6.5 per cyclodextrin molecule with each sulphobutylether unit present as its sodium salt;

20% weight/weight of glycerol; and

0.7% weight/weight of ascorbic acid:

with the formulation having been adjusted to from pH 4.0 to 5.0, preferably about pH 4.5, using aqueous sodium hydroxide solution.

23. A formulation according to claim 7 that is an aqueous solution comprising:

80 mg/g of eletriptan hemisulphate;

20% weight/weight of the sulphobutylether-beta-cyclodextrin derivative of formula (I) having an average sulphobutylether substitution of 6.5 per cyclodextrin molecule with each sulphobutylether unit present as its sodium salt;

0.10% weight/weight of polyvinylpyrrolidone; and

0.7% weight /weight ascorbic acid:

with the composition having been adjusted to from pH 4.0 to 5.0, preferably about pH 4.5, using aqueous sodium hydroxide solution.

24. A method of treating in a mammal a disease for which a $5H_{1B/1D}$ receptor agonist is indicated including treating said mammal with an effective amount of a complex according to claim 1.

25. A method of treating in a mammal migraine or preventing migraine recurrence in a mammal including treating said mammal with an effective amount of a complex according to claim 1.

26. A process for the preparation of a complex according to claim 1 which comprises combining eletriptan, or a pharmaceutically acceptable salt thereof, with the cyclodextrin derivative, or a pharmaceutically acceptable salt thereof.

27. A process for the preparation of a formulation according to claim 7 which comprises combining either (i) the complex comprising eletriptan and the cyclodextrin derivative of formula (I), or (ii) eletriptan, or a pharmaceutically acceptable salt thereof, and the cyclodextrin derivative, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable excipient, diluent or carrier.